Neuroimaging over the course of parkinson's disease: From early detection of the at-Risk patient to improving pharmacotherapy of later-Stage disease

Seminars in Nuclear Medicine

Volumn 42, Issue 6, 2012, Pages 406-414

  Seiby, John ^a,b,c   Russell, David ^a,b,c   Jennings, Danna ^a,b   Marek, Kenneth ^a,b  

^a INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^b Applicable Electronics   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CARBOMETHOXY 3 (4 IODOPHENYL) N (3 FLUOROPROPYL)NORTROPANE I 123; 2' METHOXYPHENYL(N 2' PYRIDINYL) 4 FLUOROBENZAMIDOETHYIPIPERAZINE F 18; 6 FLUORODOPA F 18; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ALPHA SYNUCLEIN; BIOLOGICAL MARKER; DOPAMINE TRANSPORTER; ENDOCANNABINOID; GLUTAMIC ACID; IOFLUPANE I 123; LEVODOPA; METABOTROPIC GLUTAMATE RECEPTOR SUBUNIT 5; METABOTROPIC RECEPTOR 5; RASAGILINE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER TYPE 2 C 11; VESICULAR MONOAMINE TRANSPORTER TYPE 2 F 18;

ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG TARGETING; DYSKINESIA; HUMAN; IMAGE ANALYSIS; MOLECULAR IMAGING; MOTOR DYSFUNCTION; NEUROFILAMENT; NEUROIMAGING; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84869001941     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.06.003     Document Type: Review

References (74)

1. Booij J, Tissingh G, Winogrodzka A, et al: Practical benefit of [123I]FPCIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71
2. Djang DS, Janssen MJ, Bohnen N, et al: SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med 2012;53:154-163
3. Jennings DL, Seibyl JP, Oakes D, et al: (123I) beta-CIT and singlephoton emission computed tomographic imaging vs clinical evaluation in parkinsonian syndrome: Unmasking an early diagnosis. Arch Neurol 2004;61:1224-1229
4. van Dyck CH, Seibyl JP, Malison RT, et al: Age-related decline in dopamine transporters: Analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10:36-43
5. Ravina B, Tanner C, Dieuliis D, et al: A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. Mov Disord 2009;24:2081-2090
6. Booij J, Habraken JB, Bergmans P, et al: Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998;39:1879-1884
7. Marek K, Jennings D, Seibyl J: Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease. Adv Neurol 2003;91:183-191
8. Olanow CW, Rascol O, Hauser R, et al: A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268- 1278
9. Marek K, Jennings D, Seibyl J: Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa. Neurology 2003;61 Suppl 3:S43-S48
10. Seibyl J, Jennings D, Tabamo R, et al: The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease. Minerva Med 2005;96:353-364
11. Marek K, Jennings D, Tamagnan G, et al: Biomarkers for Parkinson's [corrected] disease: Tools to assess Parkinson's disease onset and progression. Ann Neurol 2008;64 Suppl 2:S111-S121
12. Marek KL, Seibyl JP, Zoghbi SS, et al: [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237
13. Parkinson Study Group PRECEPT Investigators: Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-1490
14. Braak H, Rüb U, Schultz C, et al: Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis 2006;9 Suppl 3:35-44
15. Braak H, Del Tredici K: Invited article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008;70:1916-1925
16. Braak H, Ghebremedhin E, Rüb U, et al: Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121- 134
17. Brooks DJ, Pavese N: Imaging non-motor aspects of Parkinson's disease. Prog Brain Res 2010;184:205-218
18. Lang AE, Obeso JA: Challenges in Parkinson's disease: Restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3:309-316
19. Iranzo A, Valldeoriola F, Lomeña F, et al: Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eyemovement sleep behaviour disorder: A prospective study. Lancet Neurol 2011;10:797-805
20. Przuntek H, Müller T, Riederer P: Diagnostic staging of Parkinson's disease: Conceptual aspects. J Neural Transm 2004;111:201-216
21. Berendse HW, Booij J, Francot CM, et al: Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50:34-41
22. Marek K, Jennings D: Can we image premotor Parkinson disease? Neurology 2009;72 Suppl 7:S21-S26
23. Seibyl J, Russell D, Jennings D, et al: The molecular basis of dopaminergic brain imaging in Parkinson's disease. Q J Nucl Med Mol Imaging 2012;1:4-16
24. Hauber W: Involvement of basal ganglia transmitter systems in movement initiation. Prog Neurobiol 1998;56:507-540
25. Benarroch EE: Metabotropic glutamate receptors: Synaptic modulators and therapeutic targets for neurologic disease. Neurology 2008;70: 964-968
26. Jacobson KA, Nikodijević O, Padgett WL, et al: 8-(3-chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett 1993;323:141-144
27. Svenningsson P, Nomikos GG, Ongini E, et al: Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience 1997;79:753-764
28. Cauli O, Morelli M: Caffeine and the dopaminergic system. Behav Pharmacol 2005;16:63-77
29. Ferré S: An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem 2008;105:1067-1079
30. Pinna A, Corsi C, Carta AR, et al: Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol 2002;446:75-82
31. Hurley MJ, Mash DC, Jenner P: Adenosine A(2A) receptor mRNA expression in Parkinson's disease. Neurosci Lett 2000;291:54-58
32. Mishina M, Ishiwata K, Kimura Y, et al: Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [(11)C]TMSX PET. Synapse 2007;61:778-784
33. Chen JF, Sonsalla PK, Pedata F, et al: Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 2007;83:310-331
34. Popoli P, Blum D, Domenici MR, et al: A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Curr Pharm Des 2008;14:1500-1511
35. Blum D, Hourez R, Galas MC, et al: Adenosine receptors and Huntington's disease: Implications for pathogenesis and therapeutics. Lancet Neurol 2003;2:366-374
36. Alfinito PD, Wang SP, Manzino L, et al: Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 2003;23:10982-10987
37. Scattoni ML, Valanzano A, Pezzola A, et al: Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease. Behav Brain Res 2007;176:216-221
38. Chou SY, Lee YC, Chen HM, et al: CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 2005; 93:310-320
39. Calon F, Dridi M, Hornykiewicz O, et al: Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004;127:1075-1084
40. Xiao D, Bastia E, Xu YH, et al: Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 2006;26:13548-13555
41. Morelli M, Di Paolo T, Wardas J, et al: Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol 2007;83:293-309
42. Chen JF, Fredduzzi S, Bastia E, et al: Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: Implications for the treatment of dyskinesias in Parkinson's disease. Neurology 2003;61 Suppl 6:S74-S81
43. Bara-Jimenez W, Sherzai A, Dimitrova T, et al: Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61: 293-296
44. LeWitt PA, Guttman M, Tetrud JW, et al: Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002- US-005). Ann Neurol 2008;63:295-302
45. Hauser RA, Shulman LM, Trugman JM, et al: Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008;23:2177-2185
46. Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group: Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303
47. Stacy M, Silver D, Mendis T, et al: A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008; 70:2233-2240
48. Elkashef A, Vocci F, Huestis M, et al: Marijuana neurobiology and treatment. Subst Abus 2008;29:17-29
49. Herkenham M, Lynn AB, Little MD, et al: Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990;87:1932-1936
50. Pertwee RG: Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-180
51. Compton DR, Aceto MD, Lowe J, et al: In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996;277:586-594
52. Gérard CM, Mollereau C, Vassart G, et al: Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279 (Pt 1):129-134
53. Matsuda LA, Lolait SJ, Brownstein MJ, et al: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-564
54. Felder CC, Joyce KE, Briley EM, et al: Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995;48:443-450
55. Piomelli D, Beltramo M, Giuffrida A, et al: Endogenous cannabinoid signaling. Neurobiol Dis 1998;5:462-473
56. Mackie K, Stella N: Cannabinoid receptors and endocannabinoids: Evidence for new players. AAPS J 2006;8:E298-E306
57. Hashimotodani Y, Ohno-Shosaku T, Kano M: Endocannabinoids and synaptic function in the CNS. Neuroscientist 2007;13:127-137
58. Butler H, Korbonits M: Cannabinoids for clinicians: The rise and fall of the cannabinoid antagonists. Eur J Endocrinol 2009;161:655-662
59. Van Laere K, Casteels C, Lunskens S, et al: Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol Aging 2012;33:e621-e628
60. Dillon KA, Gross-Isseroff R, Israeli M, et al: Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: Effects of age and alcohol. Brain Res 1991;554:56-64
61. Marazziti D, Marracci S, Palego L, et al: Localization and gene expression of serotonin1 A (5HT1A) receptors in human brain postmortem. Brain Res 1994;658:55-59
62. Frechilla D, Cobreros A, Saldise L, et al: Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001;39:288-296
63. Muñoz A, Li Q, Gardoni F, et al: Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 2008;131:3380-3394
64. Bibbiani F, Oh JD, Chase TN: Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001;57:1829-1834
65. Kannari K, Yamato H, Shen H, et al: Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 2001;76:1346-1353
66. Lane EL, Cheetham S, Jenner P: Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J Pharmacol Exp Ther 2005;312:1124-1131
67. Politis M, Wu K, Loane C, et al: Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010;2:38ra46
68. Newman-Tancredi A, Cussac D, Quentric Y, et al: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002;303:815-822
69. Iravani MM, Tayarani-Binazir K, Chu WB, et al: In 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(?)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. J Pharmacol Exp Ther 2006;319:1225-1234
70. Durif F, Debilly B, Galitzky M, et al: Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study. Neurology 2004;62:381-388
71. Carta M, Carlsson T, Muñoz A, et al: Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res 2008;172:465-478
72. Fabbrini G, Brotchie JM, Grandas F, et al: Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389
73. Bara-Jimenez W, Bibbiani F, Morris MJ, et al: Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005;20: 932-936
74. Politis M, Wu K, Loane C, et al: Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010;75:1920-1927